HALO
HALO clinical trials: HALOZYME THERAPEUTICS, INC.
Every trial on ClinicalTrials.gov where HALOZYME THERAPEUTICS, INC. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 48
- Trials linked
- 33
- As lead sponsor
- 15
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
HALO on the catalyst calendar · HALO registry changes
- Primary completion Mar 2028Sponsor estimatePhase 3NCT0668908552 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With...Halozyme Therapeutics · Hypogonadism, MaleRecruitingHALOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 13, 2009ActualPhase 2NCT00928447Study of the Intradermal Injection of rHuPH20 or Placebo in Participants With Nickel Allergic Contact DermatitisHalozyme Therapeutics · Dermatitis, Allergic ContactCompletedHALOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 11, 2009ActualPhase 1/Phase 2NCT00318643Safety Study of Recombinant Human Hyaluronidase (Chemophase) in Combination With Mitomycin in Participants With Superficial Bladder CancerHalozyme Therapeutics · Bladder CancerCompletedHALOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 1, 2018ActualPhase 2NCT01839487PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated...Halozyme Therapeutics · Metastatic Pancreatic CancerCompletedHALOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 4, 2019ActualPhase 3NCT02715804A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus...Halozyme Therapeutics · Pancreatic Ductal CarcinomaTerminatedHALOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 11, 2019ActualPhase 1NCT03267940Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in...Halozyme Therapeutics · Cholangiocarcinoma Non-resectableTerminatedHALOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 26, 2019ActualPhase 1NCT02563548A Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab in Participants With Selected Hyaluronan High Solid TumorsHalozyme Therapeutics · NSCLCCompletedHALOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 9, 2016ActualPhase 1NCT02346370A Phase 1b Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Docetaxel in Subjects With Recurrent Previously...Halozyme Therapeutics · Non-small Cell Lung CancerTerminatedHALOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2012ActualPhase 4NCT01526733Randomized, Double Blind, 2 Way Crossover Study of CSII With, Versus Without, Pretreatment With Human HyaluronidaseHalozyme Therapeutics · Type 1 Diabetes MellitusCompletedHALOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2011ActualPhase 2NCT01194245Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Participants With Type 1 Diabetes...Halozyme Therapeutics · Diabetes Mellitus, Type 1CompletedHALOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2009ActualPhase 2NCT00774800Phase II Pharmacokinetics Study of Humalog and Humulin-R With and Without rHuPH20 in Type 1 Diabetes MellitusHalozyme Therapeutics · Type 1 Diabetes MellitusCompletedHALOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2008ActualPhase 1NCT00705536Pharmacokinetic (PK), Pharmacodynamic (PD), and Safety Study of Subcutaneously Administered Humalog® With and Without Recombinant Human...Halozyme Therapeutics · Diabetes MellitusCompletedHALOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 27, 2014ActualPhase 4NCT03662334A Study of Continuous Subcutaneous Insulin Infusion (CSII) Pump Function in Subjects With Type 1 Diabetes With Recombinant Human...Halozyme Therapeutics · Type 1 Diabetes MellitusCompletedHALOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2014ActualPhase 1/Phase 2NCT01453153Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untreated Pancreatic CancerHalozyme Therapeutics · Stage IV Pancreatic CancerCompletedHALOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2014ActualPhase 4NCT01848990CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection) Preadministered at CSII Infusion Site...Halozyme Therapeutics · Type 1 Diabetes MellitusCompletedHALOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2009ActualPhase 4NCT00773175Subcutaneous Rehydration Compared to Intravenous RehydrationHalozyme Therapeutics · DehydrationCompletedHALOLeadBAXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 30, 2008ActualPhase 4NCT00656370Study of Subcutaneous Hydration Enabled by Human Recombinant Hyaluronidase (Hylenex)Halozyme Therapeutics · HealthyCompletedHALOLeadBAXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 28, 2009ActualPhase 1NCT00803972Dose-Ranging, Pharmacokinetic (PK), Glucodynamic (GD), Safety and Tolerability Study of Subcutaneously (SC) Administered Humulin R and...Halozyme Therapeutics · Healthy VolunteersCompletedHALOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 21, 2009ActualPhase 1NCT00807963Pharmacokinetic, Safety and Tolerability Study of SC Administered Bisphosphonate With rHuPH20 vs Bisphosphonate AloneHalozyme Therapeutics · Risk Factors for or a Diagnosis of OsteoporosisCompletedHALOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2010ActualPhase 2NCT00883558Safety Study of Subcutaneously-Injected Prandial INSULIN-PH20 NP Compared to Insulin Lispro Injection in Participants With Type 1...Halozyme Therapeutics · Diabetes Mellitus, Type 1CompletedHALOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2011ActualPhase 2NCT01194258Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Patients With Type 2 Diabetes...Halozyme Therapeutics · Diabetes Mellitus, Type IICompletedHALOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2009ActualPhase 2NCT00916357Liquid Meal Study With Insulin Lispro With/Without Recombinant Human Hyaluronidase PH20 (rHuPH20) and Regular Human Insulin With rHuPH20...Halozyme Therapeutics · Diabetes Mellitus, Type 2CompletedHALOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2009ActualPhase 1NCT00862849Pharmacokinetic and Glucodynamic Crossover Study of Subcutaneously (SC) Administered Insulin Lispro + Recombinant Human Hyaluronidase...Halozyme Therapeutics · Diabetes MellitusCompletedHALOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2011ActualPhase 1NCT01275131Randomized, Double-blind, Crossover, Pharmacokinetic (PK) and Glucodynamic (GD) Study of Continuous Subcutaneous Insulin Infusion (CSII)...Halozyme Therapeutics · Type 1 Diabetes MellitusCompletedHALOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2010ActualPhase 1NCT00979875A Pharmacokinetic and Glucodynamic Study of Subcutaneously Administered Insulin Analogs With rHuPH20 Compared to Insulin Analogs AloneHalozyme Therapeutics · HealthyCompletedHALOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 23 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner